Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes

Authors:

Levy AR, Zou D, Risebrough N, Buckstein R, Kim T and Brereton N.

Publication Type:

Journal Article

Publication Name:

Current oncology

Citation:

Levy AR, Zou D, Risebrough N, Buckstein R, Kim T and Brereton N. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol. 2014;21(1):e29-40.


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies